Biotech Losers In News: Agios Pharmaceuticals (NASDAQ:AGIO), Cell Therapeutics (NASDAQ:CTIC), NewLink Genetics (NASDAQ:NLNK), Mirati Therapeutics (NASDAQ:MRTX)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) present at the Cowen and Company 34th Annual Health Care Conference at the Boston Marriott Copley Place. Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock performance was -5.69% in last session and finished the day at $29.48. Traded volume was 263,884 million shares in the last session and the average volume of the stock remained 254.15 million shares. Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider ownership … Continue reading Biotech Losers In News: Agios Pharmaceuticals (NASDAQ:AGIO), Cell Therapeutics (NASDAQ:CTIC), NewLink Genetics (NASDAQ:NLNK), Mirati Therapeutics (NASDAQ:MRTX)

Best Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), JetBlue Airways Corporation (NASDAQ:JBLU), First Midwest Bancorp Inc. (NASDAQ:FMBI), Prothena Corporation plc (NASDAQ:PRTA), RCI Hospitality (NASDAQ:RICK)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 297,968 shares at the public offering price of $110.75 per share. The exercise of the over-allotment option brought the total number of shares of common stock sold by Agios to 2,284,423 shares and … Continue reading Best Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), JetBlue Airways Corporation (NASDAQ:JBLU), First Midwest Bancorp Inc. (NASDAQ:FMBI), Prothena Corporation plc (NASDAQ:PRTA), RCI Hospitality (NASDAQ:RICK)

Kosmos Energy (NYSE:KOS)‘s stock had its “hold” rating reissued by equities research analysts at Citigroup Inc. in a research note issued to investors on Monday. They currently have a $9.50 target price on the stock, down from their previous target price of $12.00. Kosmos Energy Ltd. (NYSE:KOS) belongs to Basic Materials sector. Its net profit margin is 25.30% and weekly performance is -15.90%. On last … Continue reading Market Movers: Kosmos Energy Ltd. (NYSE:KOS), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Potlatch Corporation (NASDAQ:PCH), Teleflex Incorporated (NYSE:TFX), BBVA Banco Frances SA (NYSE:BFR)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), announced new data from the ongoing Phase 1 dose escalation study of AG-221 as a single agent in patients with IDH2-mutant positive advanced hematologic malignancies. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) belongs to Healthcare sector. Its net profit margin is -82.60% and weekly performance is 11.46%. On last trading day company shares ended up $107.30. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) distance from 50-day simple … Continue reading Ever Green Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), The AES Corporation (NYSE:AES), Wynn Resorts Ltd. (NASDAQ:WYNN), Pioneer Energy Services (NYSE:PES), NovaBay Pharmaceuticals (NYSEMKT:NBY)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)